• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ: APTO )

0.2790 +0.1088 (+63.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Recap: Aptose Biosciences Q4 Earnings
March 26, 2024
Via Benzinga
Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 26, 2024
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Aptose Biosciences's Earnings: A Preview
March 25, 2024
Via Benzinga
Aptose Biosciences: Q3 Earnings Insights
November 09, 2023
Via Benzinga
Expert Ratings for Aptose Biosciences
September 07, 2023
Via Benzinga
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
January 31, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts
January 26, 2024
Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024! 
Via InvestorPlace
Topics Economy Workforce
Exposures Economy Layoff
Why Is SU Group (SUGP) Stock Moving Today?
January 26, 2024
SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Why Is Aptose Biosciences (APTO) Stock Down Today?
January 26, 2024
Aptose Biosciences stock is sliding lower on Friday as investors react to a public offering and private placement for APTO shares. 
Via InvestorPlace
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
January 26, 2024
Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 26, 2024
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! 
Via InvestorPlace
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 30, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
November 09, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
Company to Hold Clinical Update Webcast; Details Forthcoming 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know
August 11, 2023
Via Benzinga
Aptose Reports Results for the Second Quarter 2023
August 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
July 26, 2023
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap